Description: Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, is engaged in the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead product candidates include VB-111, a gene-based biologic, which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; in Phase II clinical trials to treat thyroid cancer; and in Phase I/II clinical trials for the treatment of ovarian cancer, as well as VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Or Yehuda, Israel.
Home Page: www.vblrx.com
VBLT Technical Analysis
8 HaSatat Street
Hevel Modi'in,
7178106
Israel
Phone:
972 8 993 5000
Officers
| Name | Title |
|---|---|
| Prof. Dror Harats M.D. | CEO & Director |
| Dr. Eyal Breitbart Ph.D. | Sr. VP of Research & Operations |
| Dr. Naamit Sher Ph.D. | Sr. VP of Drug Devel. & Regulatory Affairs |
| Dr. Erez Feige M.B.A., Ph.D. | Sr. VP of Bus. Operations |
| Mr. Samuel Backenroth | Chief Financial Officer |
| Advocate Ayelet Horn | Gen. Counsel |
| Deborah Scott | Managing Director of Financial Communications |
| Dr. Tami Rachmilewitz M.D. | Sr. VP of Clinical Devel. |
| Dr. Yael Cohen | Medical Director |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3545 |
| Price-to-Sales TTM: | 9.6294 |
| IPO Date: | 2014-10-01 |
| Fiscal Year End: | December |
| Full Time Employees: | 41 |